EVEXTA-BIO
19.6.2024 17:08:31 CEST | Business Wire | Press release
Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Shawn M. Leland, PharmD, RPh as Chairman of the Board of Directors.
Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. Throughout his career, Shawn has successfully advanced novel oncology assets and programs, raised substantial capital for various ventures, negotiated major global licensing agreements, and established strategic partnerships. His extensive experience in leading biotech startups, raising capital and executing strategic collaborations will be a major benefit to Evexta Bio in its growth and corporate development strategy.
Most recently, Shawn was the Interim CEO and Board Director of ForeBio, where he led the company through a phase 2 study with registrational intent and closed a $75M Series D financing.
In July 2019, Shawn founded Elevation Oncology, where he served as Chief Business Officer and Board Director, and later as CEO until January 2023. During his mandate, the company advanced multiple novel targeted oncology assets. Shawn raised over $200M in capital, which included a $100M IPO. Shawn grew Elevation Oncology from zero to more than 50 employees.
Shawn was Head of Business Development at Verastem Oncology from 2017 – 2019 and Argos Therapeutics from 2013 – 2017 where he played a pivotal role in each company’s corporate development strategy leading multiple partnerships and licensing transactions. Shawn started his career with pharmaceutical and biotechnology companies, ARIAD Pharmaceuticals and Eli Lilly. Shawn holds a PharmD from Albany College of Pharmacy.
Alain Chevallier, former Chairman of the board of Directors of Evexta Bio, said: “I'm pleased to be handing over the chairmanship to a great professional of the oncology and biotech field as Shawn, who brings new valuable perspectives to Evexta Bio, and I will continue, as Vice-Chairman, to be fully committed to the success of the Company.”
Scott Filosi, CEO of Evexta Bio added: “I am delighted to welcome Shawn as Chairman of the Board of Directors. His experience and expertise in oncology and strategic development of biotechnology companies are real assets for Evexta Bio. I’m looking forward to working with him to accelerate the mission of Evexta Bio.”
Shawn M. Leland, Chairman of the Board of Directors of Evexta Bio, said: "I’m looking forward to joining the team of Evexta Bio in such a pivotal moment of its development. Evexta Bio has tremendous potential and I thank the members of the Board of Directors for their trust.”
About Evexta Bio (https://www.evextabio.com)
Evexta Bio is a biopharmaceutical company exploring the new frontiers of oncology in search of daring novel therapeutic approaches with the potential to save lives. Now, in the clinic, the company is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications:
- Rupitasertib, an optimized S6K inhibitor with efficient AKT1/AKT3 control of compensatory AKT feed-back loop. The oral anti-tumor agent is expected to enter phase 2 clinical trial in ESR1mt ER+ HER2- advanced breast cancer.
- EVX020, a sole-in-class KIF20A kinesin inhibitor having shown potent nonclinical efficacy in hematological and solid tumor models. Two strategies are under assessment, development of EVX020 as a prodrug and as a payload for antibody-drug conjugate (ADC).
Founded by Truffle Capital, supported by Merck KGaA (Darmstadt, Germany) as shareholder, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA. The company is supported by seasoned management team, board of directors and medical advisory board.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619024966/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom